Crystal Structures of the Lyn Protein Tyrosine Kinase Domain in Its Apo- and Inhibitor-bound State

被引:57
作者
Williams, Neal K. [1 ]
Lucet, Isabelle S. [1 ]
Klinken, S. Peter [4 ]
Ingley, Evan [2 ,3 ,4 ]
Rossjohn, Jamie [1 ]
机构
[1] Monash Univ, Dept Biochem & Mol Biol, Prot Crystallog Unit, Sch Biomed Sci, Clayton, Vic 3800, Australia
[2] Univ Western Australia, Cell Signalling Grp, Western Australian Inst Med Res, Perth, WA 6000, Australia
[3] Univ Western Australia, Med Res Ctr, Perth, WA 6000, Australia
[4] Univ Western Australia, Lab Canc Med, Perth, WA 6000, Australia
基金
英国医学研究理事会;
关键词
SRC FAMILY KINASES; ERYTHROPOIETIN-INDUCED DIFFERENTIATION; MYELOGENOUS LEUKEMIA-CELLS; BCR-ABL; PROSTATE-CANCER; DEFICIENT MICE; RESISTANT; ACTIVATION; REGRESSION; BMS-354825;
D O I
10.1074/jbc.M807850200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The Src-family protein-tyrosine kinase (PTK) Lyn is the most important Src-family kinase in B cells, having both inhibitory and stimulatory activity that is dependent on the receptor, ligand, and developmental context of the B cell. An important role for Lyn has been reported in acute myeloid leukemia and chronic myeloid leukemia, as well as certain solid tumors. Although several Src-family inhibitors are available, the development of Lyn-specific inhibitors, or inhibitors with reduced off-target activity to Lyn, has been hampered by the lack of structural data on the Lyn kinase. Here we report the crystal structure of the non-liganded form of Lyn kinase domain, as well as in complex with three different inhibitors: the ATP analogue AMP-PNP; the pan Src kinase inhibitor PP2; and the BCR-Abl/Src-family inhibitor Dasatinib. The Lyn kinase domain was determined in its "active" conformation, but in the unphosphorylated state. All three inhibitors are bound at the ATP-binding site, with PP2 and Dasatinib extending into a hydrophobic pocket deep in the substrate cleft, thereby providing a basis for the Src-specific inhibition. Analysis of sequence and structural differences around the active site region of the Src-family PTKs were evident. Accordingly, our data provide valuable information for the further development of therapeutics targeting Lyn and the important Src-family of kinases.
引用
收藏
页码:284 / 291
页数:8
相关论文
共 45 条
[1]  
Bates RC, 2001, CANCER RES, V61, P5275
[2]   Proteomic analysis of the venom of Heterometrus longimanus (Asian black scorpion) [J].
Bringans, Scott ;
Eriksen, Soren ;
Kendrick, Tulene ;
Gopalakrishnakone, P. ;
Livk, Andreja ;
Lock, Robert ;
Lipscombe, Richard .
PROTEOMICS, 2008, 8 (05) :1081-1096
[3]  
Chin H, 1998, BLOOD, V91, P3734
[4]   Src-related protein tyrosine kinases in hematopoiesis [J].
Corey, SJ ;
Anderson, SM .
BLOOD, 1999, 93 (01) :1-14
[5]   Deficiency of Src family kinases Fgr and Hck results in activation of erythrocyte K/Cl cotransport [J].
DeFranceschi, L ;
Fumagalli, L ;
Olivieri, O ;
Corrocher, R ;
Lowell, CA ;
Berton, G .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (02) :220-227
[6]   BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571 [J].
Donato, NJ ;
Wu, JY ;
Stapley, J ;
Gallick, G ;
Lin, H ;
Arlinghaus, R ;
Talpaz, M .
BLOOD, 2003, 101 (02) :690-698
[7]   A critical role for Lyn in acute myeloid leukemia [J].
Dos Santos, Ceric ;
Demur, Ceile ;
Bardet, Valeie ;
Prade-Houdellier, Nais ;
Payrastre, Bernard ;
Recher, Christian .
BLOOD, 2008, 111 (04) :2269-2279
[8]   Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].
Druker, BJ ;
Talpaz, M ;
Resta, DJ ;
Peng, B ;
Buchdunger, E ;
Ford, JM ;
Lydon, NB ;
Kantarjian, H ;
Capdeville, R ;
Ohno-Jones, S ;
Sawyers, CL .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037
[9]  
Golas JM, 2003, CANCER RES, V63, P375
[10]   Lyn is a target gene for prostate cancer:: Sequence-based inhibition induces regression of human tumor xenografts [J].
Goldenberg-Furmanov, M ;
Stein, I ;
Pikarsky, E ;
Rubin, H ;
Kasem, S ;
Wygoda, M ;
Weinstein, I ;
Reuveni, H ;
Ben-Sasson, SA .
CANCER RESEARCH, 2004, 64 (03) :1058-1066